terminally-differentiated effector-memory T cells until 6 months post-UCBT, at which time the polyfunctionality of antigen-specific CD8 + T cells was re-established. Finally, the frequency of PD-1 + CD8 + T cells was significantly higher in subjects who subsequently experienced leukemic relapse. This study informs the biological properties of UCB-derived CD8 + T cells and provides a rationale for the characteristics of UCBT in terms of immune reconstitution and OI. These results also suggest that elevated frequency of PD-1 + CD8 + T cells could be associated with leukemic relapse in pediatric UCBT recipients.
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INTRODUCTION
Umbilical cord blood (UCB) transplantation (UCBT) is commonly used to treat a variety of hematologic diseases in children. 1, 2 Reduced incidence of graft versus host disease (GvHD) compared to BM transplantation (BMT) was documented following UCBT.
3
UCBT was associated with slow engraftment, delayed CD8 + T cells recovery, high incidence of graft failure, and high incidence of opportunistic infections (OI) in the first 3 to 6 months post-transplantation. [4] [5] [6] Approximately 20% of pediatric UCBT recipients will also experience leukemic relapse, a frequency similar to that observed in BMT.
7
In the context of BMT, graft-derived CD8 + T cells are known to shield the graft recipient against OI and leukemic relapse. 8, 9 UCBT involves the transfer of multiple cell subtypes into the recipient, including large amounts of CD8 + T lymphocytes. While the presence of UCB-derived CD8 + T cells in the graft inoculums can provide some degree of protection from OI and leukemic relapse to UCBT recipients, 10, 11 recent studies suggest that these cells might only mediate minimal levels of antiviral immunity. 12, 13 The relative inefficacy of UCB-derived CD8 + T cells to prevent OI and their failure to prevent leukemic relapse in some patients is not well understood.
Based on cell-surface expression of CD45RA and CCR7, CD8 + T cells can be classified as naïve, central memory, effector memory, and terminally differentiated. 14 Using peptide-MHC tetramers, antigen-specific CD8 + T cells isolated from UCB were shown to be mostly naïve and clonally diversified. In addition, they produced significantly less IFN-γ but were more likely to achieve terminal differentiation and less likely to exhibit
For personal use only. on . by guest www.bloodjournal.org From bifunctional properties (IFN-γ production and cytolytic activity) as compared with T lymphocytes derived from adult blood. 15 In theory, these properties are compatible with low incidence of GvHD and high incidence of OI. However, little is known regarding the fate of CD8 + T cells once they are transplanted into UCBT recipients.
The objective of this study was to characterize the reconstitution of CD8 + T cells in an antigen-specific repertoire. A2/Melan-A-specific T cells represent one of the only preimmune T cell repertoires that can be studied in humans. 15, 17, 18 Here we provide evidence that some UCB-derived CD8 + T lymphocytes persisted in paediatric recipients in the first 6 months post-UCBT. Their clonal diversity reached a nadir at 3 months post-UCBT. At this point, the CD8 + compartment was predominantly comprised of terminally-differentiated T cells and both CD4 + and CD8 + subsets were enriched in cells expressing programmed death 1 (PD-1). From 6 months post-UCBT, the CD8 + T cell repertoire was progressively restored with a naïve, diversified, and polyfunctional population. Finally, higher frequencies of PD-1 + CD8 + T cells were detected at 2 and 6 relative to the UCBT procedure. Granulocyte-colony stimulating factor (G-CSF) was also administered starting on day +1. Two subjects were lost to follow-up. Transplant procedure was detailed in Dalle et al. 19 Clinical characteristics of study subjects are summarized in Table 1 . Figure S1 ). Analysis of cell-surface markers was Immunophenotyping was performed using the following mAbs: PE-or APC-conjugated anti-CD8 (RPA-T8), PE-Cy7-conjugated anti-CCR7 (3D12), and FITC-conjugated anti-CD45RA (HI100) (BD Biosciences All analyses were performed using GraphPad Prism version 4 (GraphPad Software, San Diego, CA). This indicates that the relative abundance of antigen-specific CD8 + T cells depends on the reconstitution of the CD4 + and CD8 + T cell compartments.
Generation of T cell microcultures.

RESULTS
Ex vivo detection of
Detection of Melan-A-specific T cells post-UCBT after polyclonal stimulation.
The early post-UCBT period is characterized by very low numbers of circulating CD8 + T cells. 25 To circumvent this limitation, PHA stimulation was used to expand T cells independent of antigenic specificity. 26 After 7-10 days of expansion, A2/Melan-A + CD8 + T cells were detected at a frequency > 0.01% in 9 of 10 grafts and 8 of 9 study subjects at 1 month post-UCBT ( Figure 1B ). These cells were also detected in 2 of 6 and 1 of 5 patients at 2 months and 3 months post-UCBT, respectively, and in the majority of and 36 months post-UCBT ( Figure 2A ). It is unlikely that early clonotypes were of recipient origin, as 100% donor chimerism was observed at 3 and 6 months post-UCBT in most study subjects. These results are consistent with rare UCB-derived T cells transiently persisting in the recipient up to 6 months after UCBT, followed by progressive repletion of T cell repertoire diversity via thymopoïesis.
Phenotypic reconstitution of total and A2/Melan-A + CD8
+ T cells following UCBT.
Expression of CD45RA and CCR7 was monitored in total CD8 + T cells and A2/Melan- For
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PD-1 expression is associated with leukemic relapse. Eight study subjects experienced leukemic relapse during follow-up (« relapsers »), of whom 6 relapsed > 6 months post-UCBT ( Figure S3 ). There were no significant differences in the naïve-memory phenotype of CD8 + T cells at 2 or 3 months post-UCBT in relapsers compared to nonrelapsers ( Figure S3 ). However, there was a trend towards higher frequencies of EM T cells (p = 0.0823) and significantly lower CD4 + T cells counts in relapsers at 6 months (p = 0.0376) (Fig. 6A, S6 ). There was no significant difference in total CD8 + T cell counts between relapsers and nonrelapsers ( Figure 6B ). Finally, the frequency of PD1 + CD8 + T cells was significantly higher in relapsers than in nonrelapsers at 2 and 6 months (p = 0.0079 and p = 0.0364, respectively) ( Figure 6C -6D and S5G). The frequency of PD-1 + CD4 + T cells was also higher in relapsers at 6 months, but this difference was not statistically significant ( Figure S5F and S5H). Taken together, these results suggest that a high frequency of PD-1 + CD8 + T cells in UCBT recipients during the early post-transplant period could be associated with subsequent leukemic relapse.
DISCUSSION
UCB is increasingly being used as an alternative source of hematopoietic stem cells for the treatment of various blood disorders in cases where a suitably-matched donor is not readily available. However, clinical outcomes associated with UCBT differ from those observed following BMT, particularly in terms of GvHD, graft failure, and OI. Leukemic relapse can occur following UCBT, particularly in patients with poor immune reconstitution. 31 To explore the cellular and molecular basis of these outcomes, we examined the reconstitution of antigen-specific T lymphocytes in a group of pediatric and/or e) the differential incidence of GvHD and OI, which could not be assessed in the context present study. PD-1 expression is preferentially observed in EM and EMRA T cells. 44, 45 Overall, our results are consistent with UCB CD8 + T cells undergoing massive oligoclonal expansion while acquiring a skewed terminally-differentiated and exhausted phenotype following transfer into the recipients. These results provide a rationale for the increased susceptibility to OI and comparatively reduced incidence of acute GvHD observed in UCBT recipients. 5 These conclusions would be strengthened by a comparison between UCBT and BMT, which should be addressed in future studies. PD-1 expression and/or the interaction between PD-1 and its ligands PD-L1 and PD-L2 could
20
represent attractive targets for interventions aiming to reduce the incidence of OI following UCBT.
Finally, 8 subjects experienced leukemic relapse, including 6 who relapsed later than 6 months post-UCBT, a time at which the polyfunctionality profile of antigen-specific CD8 + T cells had already completely recovered. Although the frequency of PD1 + CD8 + T cells in the first 3 months post-UCBT was high in every subject, it was significantly higher in relapsers than in nonrelapsers at 2 and 6 months. Lower CD4 + T cell counts and higher frequency of EM CD8 + T cells frequency were also observed in relapsers, potentially highlighting the importance of cooperation between CD4 + and CD8 + T cells for generation, maintenance and/or efficacy of the graft versus leukemia effect. Lower frequencies of CD28 -CD8 + and EMRA CD8 + T cells following allogeneic stem cell transplantation were previously associated with a greater risk of relapse of underlying hematologic malignancies. 37 To our knowledge, the present study is the first to report an association between the frequency of PD-1 + CD8 + T cells and subsequent leukemic relapse. This should be confirmed in larger series and additional studies will be required to determine whether increased frequency of PD-1 + CD8 + T cells is the underlying cause or merely a consequence of the ensuing relapse. However, these results suggest that this parameter could be used as a potential prognostic factor for leukemic relapse in pediatric UCBT recipients.
For Conditioning regimen and GvHD prophylaxis were described under Materials and Methods. Twenty-three of 26 subjects (88.5%) were transplanted to treat persistent malignant disease. The major cause of post-transplant mortality was leukemic relapse (n = 5). The frequency of leukemic relapse was calculated on subjects who suffered from hematologic malignancies (n = 23). Subjects lost to follow-up (n = 2) were not included in the analysis. ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; AML: acute myeloid leukemia; FHLH: familial hemophagocytic lymphohistiocytosis;
GvHD: graft-versus-host disease. Error bars represent the range. n represents the number of subjects.
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